Premium
Cisplatin and 5‐fluorouracil chemotherapy in advanced or recurrent squamous cell carcinoma of the head and neck
Author(s) -
Mercier Richard J.,
Neal G. David,
Mattox Douglas E.,
Gates George A.,
Pomeroy Thomas C.,
von Hoff Daniel D.
Publication year - 1987
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19871201)60:11<2609::aid-cncr2820601105>3.0.co;2-e
Subject(s) - medicine , cisplatin , chemotherapy , fluorouracil , radiation therapy , oncology , epidermoid carcinoma , progressive disease , complete response , head and neck , surgery , basal cell
Fifty‐three patients with advanced or recurrent squamous cell carcinoma of the head and neck (SCCHN) were treated with bolus cisplatin (CDDP) and 96‐hour infusion of 5‐fluorouracil (5‐FU). Twenty‐six patients with advanced disease (21 T 4 and/or N3 ) and no prior therapy (NPT) received 2 to 3 cycles of chemotherapy prior to surgery and/or radiation. There were four complete responses (CR) and 12 partial responses (PR) to chemotherapy for an overall response rate of 61%. In 20 patients with locally recurrent or disseminated disease there was one CR and six PR for an overall response rate of 35%. All but one responding patient in both groups showed clear evidence of tumor response after the initial cycle of chemotherapy. Two of the five complete responders required at least three courses to achieve CR. Disease‐free survival was poor: only five of 26 patients in the NPT group remain alive and free of disease 8 to 28 months from initial therapy. CDDP and 5‐FU is an active combination for SCCHN, but survival benefit remains to be proven.